Literature DB >> 8702987

Purification and properties of rat liver nuclear proteins that interact with the hepatitis B virus enhancer 1.

M J Kosovsky1, B Huan, A Siddiqui.   

Abstract

The hepatitis B virus enhancer 1 element plays a fundamental role in the liver-specific regulation of hepatitis B virus gene expression. A central region of enhancer 1, the enhancer core domain, contains at least four cis-acting sequence motifs that are essential for enhancer 1 activity. In this study, we have investigated an essential motif within the core domain previously defined as footprint V (FPV). Transient transfection analyses demonstrate that FPV is capable of independently functioning in a liver-specific manner to activate transcription. Therefore, to further examine the liver-specific properties of FPV-mediated enhancer 1 activity, we have carried out the biochemical purification and characterization of FPV binding activity from rat liver nuclei. This study has conclusively identified hepatocyte nuclear factor 3beta (HNF-3beta), a liver-enriched member of the HNF-3/forkhead gene family, as the predominant purified protein that interacts with the FPV motif. Moreover, a cellular protein(s) that copurified with HNF-3beta specifically interacts with a novel sequence motif that partially overlaps FPV. Since this novel motif contains a palindromic sequence, we have tentatively referred to the protein(s) that binds to this site as palindrome-binding factor (PBF). Additional evidence indicates that HNF-3beta and PBF cooperatively interact with enhancer 1. Therefore, this study supports the hypothesis that FPV-mediated enhancer activity involves a cooperative interplay between HNF-3beta and at least one other enhancer 1-binding protein, PBF.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8702987     DOI: 10.1074/jbc.271.36.21859

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  8 in total

1.  The enhancer I core region contributes to the replication level of hepatitis B virus in vivo and in vitro.

Authors:  C T Bock; N P Malek; H L Tillmann; M P Manns; C Trautwein
Journal:  J Virol       Date:  2000-03       Impact factor: 5.103

2.  Interaction between STAT-3 and HNF-3 leads to the activation of liver-specific hepatitis B virus enhancer 1 function.

Authors:  Gulam Waris; Aleem Siddiqui
Journal:  J Virol       Date:  2002-03       Impact factor: 5.103

3.  Mitochondrially associated hepatitis B virus X protein constitutively activates transcription factors STAT-3 and NF-kappa B via oxidative stress.

Authors:  G Waris; K W Huh; A Siddiqui
Journal:  Mol Cell Biol       Date:  2001-11       Impact factor: 4.272

4.  Transcriptional and posttranscriptional control of hepatitis B virus gene expression.

Authors:  Susan L Uprichard; Stefan F Wieland; Alana Althage; Francis V Chisari
Journal:  Proc Natl Acad Sci U S A       Date:  2003-01-27       Impact factor: 11.205

5.  Effects of interferon-α/β on HBV replication determined by viral load.

Authors:  Yongjun Tian; Wen-ling Chen; Jing-hsiung James Ou
Journal:  PLoS Pathog       Date:  2011-07-28       Impact factor: 6.823

6.  Impact of Nucleotide Mutations at the HNF3- and HNF4-Binding Sites in Enhancer 1 on Viral Replication in Patients with Chronic Hepatitis B Virus Infection.

Authors:  Eun-Young Cho; Hyung-Jin Kim; Channy Park; Hong-Seob So; Rae Kil Park; Haak Cheoul Kim
Journal:  Gut Liver       Date:  2013-06-11       Impact factor: 4.519

7.  Design, synthesis, and molecular hybrids of caudatin and cinnamic acids as novel anti-hepatitis B virus agents.

Authors:  Li-Jun Wang; Chang-An Geng; Yun-Bao Ma; Jie Luo; Xiao-Yan Huang; Hao Chen; Ning-Jia Zhou; Xue-Mei Zhang; Ji-Jun Chen
Journal:  Eur J Med Chem       Date:  2012-05-26       Impact factor: 6.514

8.  Transcriptional regulators of human oncoviruses: structural and functional implications for anticancer therapy.

Authors:  Ivona Nečasová; Martin Stojaspal; Edita Motyčáková; Tomáš Brom; Tomáš Janovič; Ctirad Hofr
Journal:  NAR Cancer       Date:  2022-03-03
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.